Clinical trials: Malignant Tumor Liver
Advanced Solid Tumor, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04242199
- Testing
- INCB099280
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 182 people
- Sponsor
- Incyte Corporation
Hepatocellular Carcinoma, Perfusion Scanner
Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib.
Hepatocellular carcinoma (HCC) is a hypervascular tumor. The reference treatment of advanced forms of stage C according to the Barcelona classification (BCLC C) is sorafenib, a multi-target tyrosine kinase inhibitor with…
- Trial name
- HCC-CTPerf (NCT03140332)
- Testing
- Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Colorectal Cancer, Liver Tumor
Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases
The aim of this study is to explore whether target therapy in combination with chemotherapy as treatment could improve survival or tumor response in patients undergoing Synchronic Hepatectomy for Colorectal Liver Metastases.
- Trial name
- NCT01677728
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xu jianmin
Carcinoma, Hepatocellular, Liver Neoplasms
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein…
- Conditions
- Carcinoma, Hepatocellular, Liver Neoplasms, Sintilimab, Portal Vein Tumor Thrombus
- Trial name
- NCT04618367
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better.
- Trial name
- RADIANT (NCT07312292)
- Testing
- Angiotensin II (Giapreza®), Yttrium-90 radioembolization
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Niek Wijnen
Cancer, Solid Tumor
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system.
- Conditions
- Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases
- Trial name
- CAT_PB (NCT06065592)
- Testing
- Palbociclib, Rivaroxaban, SNP
- Where
- 2 sites in Lebanon
- Volunteers
- 500 people
- Sponsor
- Lebanese University
Hepatocellular Carcinoma
HR Combined With FOLFOX4 for HCC With PVTT
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) is the conventional ''curative'' treatment for HCC.
- Trial name
- NCT02452853
- Testing
- HR, FOLFOX4
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Radiotherapy
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
This is a single-center, single-arm, open-label study that includes patients meeting the inclusion criteria (liver-GTV volume < 700ml or estimated liver-GTV V5 < 300ml) with hepatocellular carcinoma with diffuse tumor thrombosis…
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, Tislelizumab, Tumor Thrombosis
- Trial name
- NCT06233981
- Testing
- Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, Tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.
Hepatocellular carcinoma is prone to invade the portal vein and form portal vein thrombosis, and patients in this period are directly included in the advanced stages, i.e. Barcelona clinical liver cancer stage C.
- Trial name
- NCT06248528
- Testing
- Liver resection, Locoregional therapy
- Where
- China
- Volunteers
- 1,076 people
- Sponsor
- Chen Xiaoping
Neuroendocrine Tumors, Liver Metastases
Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases
The objective is to investigate the impact of intra-arterial administration of 177Lu-dotatate on the intrahepatic biodistribution in patients with NET liver metastases.
- Trial name
- LUTIA (NCT03590119)
- Testing
- Lutetium Lu 177-DOTATATE
- Where
- 3 sites in Netherlands
- Volunteers
- 26 people
- Sponsor
- Marnix Lam
Colorectal Cancer, MSS
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
This is a multi-center, non-randomised Phase 1b study to evaluate the safety and tolerability of ATP128 alone or in combination with BI 754091 and of heterologous prime-boost ATP128 + VSV-GP128 in combination with BI 754091.
- Conditions
- Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- KISIMA-01 (NCT04046445)
- Testing
- ATP128, BI 754091, VSV-GP128
- Where
- 12 sites in United States, Belgium and 2 more
- Volunteers
- 96 people
- Sponsor
- Amal Therapeutics
Breast Cancer, Pancreas Cancer
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
- Conditions
- Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer
- Trial name
- NCT03199586
- Testing
- NP-G2-044
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Hepatitis B Infection, Malignant Solid Neoplasm
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
This phase III trial studies the effect of hepatitis B antiviral (anti-HBV) therapy in preventing liver complications in patients with chronic or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid…
- Trial name
- NCT03887702
- Testing
- Best Practice, Entecavir, Tenofovir Alafenamide
- Where
- 193 sites in United States, Guam
- Volunteers
- 4 people
- Sponsor
- SWOG Cancer Research Network
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
- Trial name
- DUET-1 (NCT05120271)
- Testing
- CAR-GPC3 T Cells
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Sotio Biotech Inc.
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma
- Trial name
- NCT00831844
- Testing
- cixutumumab, laboratory biomarker analysis
- Where
- 105 sites in United States, Australia and 1 more
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Hepatocellular Carcinoma
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with hepatocellular…
- Trial name
- NCT03468231
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Urologic Cancer
In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients
The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma.
- Conditions
- Head and Neck Cancer, Urologic Cancer, Lung Cancer, Breast Cancer
- Trial name
- FUTURE (NCT06827639)
- Testing
- blood collection, tissue specimen collection
- Where
- France
- Volunteers
- 640 people
- Sponsor
- Assistance Publique Hopitaux De Marseille